Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GK567 for deodorization of fungating tumors
NCT01541930Phase 3Completed
- Sponsor
- Galderma
- Start
- Apr 2012
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of metronidazole in cutaneous neoplasm, sponsored by Galderma. Primary endpoint: Success Rate (Smell Score 0 or 1) at Day 14. Started Apr 2012; status: completed.
02
Drugs
metronidazole
03
Conditions
cutaneous neoplasm
Beyond the preview
Go deeper on NCT01541930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01541930.